Ludwig Institute for Cancer Research Limited

Other

Cornell University

Memorial Sloan Kettering Cancer Center

Biotest Pharma Gmbh

Michael Pfreundschuh

Ugur Sahin

Ozlem Tureci

Lloyd J Old

Yao-tseng Chen

Matthew J Scanlan

Ali O Gure

&Ouml;zlem T&uuml;reci

Stefan Stevanovic

Alexander Knuth

Hans Georg Rammensee

Solam Tsang

Jan Wouter Drijfhout

Christoph Renner

Elke J&auml;ger

Knuth Alexander

Klaus-Dieter Preuss

Ali Gur&eacute;

Hans-Georg Rammensee

Georg Rammensee

The invention relates, at least in part, to the identification of paratarg as a paraprotein target in various malignant and non-malignant gammopathies, which can be used in the diagnosis and treatment of either.

Methods and compositions for diagnosis and treatment of malignant and non-malignant gammopathies

Peptides which have an amino acid sequence identical to sequences found in tumor rejection antigen precursors, such as NY-ESO-1, and SSX-2, are disclosed. These peptides bind to MHC-Class II molecules, such as HLA-DR molecules, and provoke proliferation of CD4+ cells.

Isolated peptides which bind to MHC Class II molecules, and uses thereof

The invention relates to members of the SSX family of genes, as well as their uses. Also a part of the invention are peptides derived from SSX molecules and the NY-ESO-1 molecule, which form complexes with HLA molecules, leading to lysis of cells presenting these complexes, by cytolytic T cells.

Isolated nucleic acid molecules encoding isolated peptides which correspond to contiguous amino acids of an SSX molecule or NY-ESO-1 and uses thereof

Peptides which have an amino acid sequence identical to sequences found in tumor rejection antigen precursors, such as NY-ESO-1, and SSX-2, are disclosed. These peptides bind to MHC-Class II molecules, such as HLA-DR molecules, and provoke proliferation of CD4&plus; cells.

Isolated peptides which bind to MHC class II molecules, and uses thereof

The invention relates to a peptide with the sequence of RLLEFYLAM, methods for the use of the peptide, and antisera and monoclonal antibodies against the peptide. The peptide is derived from the NY-ESO-1 molecule, which form complexes with HLA molecules, leading to lysis of cells presenting these complexes, by cytolytic T lymphocytes.

Tumor associated peptide and uses thereof

Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules

The invention described methods for identifying a molecule of interest, as well as nucleic acid molecules which encode it, and binding partners for it. A cDNA library from a cell expressing the target is prepared, and expressed in host cells. Lysates of the host cells are screened with a sample, treated to remove interfering binding partners. The treatment involves contact of the sample to lysates of untransfected host cells, and host cells transfected or transformed with the same vector used to make the cDNA library. Also a part of the invention are antigens and cDNA identified using the methodology.

Method for identifying or isolating a molecule and molecules identified thereby

The invention relates to assays for determining breast cancer or melanoma. It has been found that the accuracy of such assays can be improved by assaying samples for three or more known tumor rejection antigen precursors. For breast cancer, the tumor rejection antigen precursors known as SCP-1, NY-ESO-1, and SSX-2 are assayed. For melanoma, SSX-2, NY-ESO-1, and MAGE-3 are assayed. Additional known tumor rejection antigen precursors can also be determined to confirm the assays. It is preferred to carry these out via polymerase chain reactions.

Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith

The invention relates to members of the SSX family of genes, as well as their uses.

SSX family proteins

The invention involves the recognition of a previously unidentified protein family which belongs to, the human SCP family. The members of the family, such as SCP-2 and rat SCP-3 homolog are markers for cell transformation. Diagnostic and therapeutic uses of these protein and related molecules are taught.

Isolated SCP proteins and uses thereof

Isolated nucleic acid molecules encoding SSX family members and thereof

The invention relates to members of the SSX family of genes, as well as to their uses.

Methods for determining presence of cancer in a sample by determining expression of an SSX gene

The invention relates to the isolation of a nucleic acid molecule which encodes a cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen, and peptides derived from it.

Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof

The invention involves the recognition of a previously unidentified protein family which belongs to the human SCP family. The members of the family, such as SCP-2 and rat SCP-3 homolog, are markers for cell transformation. Also disclosed is the analysis of SCP proteins association with nuclear bodies. Diagnostic and therapeutic uses of these proteins and related molecules are taught.

Isolated nucleic acid molecules which encode SCP proteins, and uses thereof

The invention involves the recognition of a previously identified protein, SCP-1, as a marker for cell transformation. Diagnostic and therapeutic uses of this protein and related molecules are taught. Also disclosed is a method for identifying substances which are immunoreactive and indicative of pathological conditions, using normal cells as source material.

Growing community of inventors

Homburg/Saar, Germany

Michael Pfreundschuh